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Background: Not enough data are available about the effectiveness of consensus interferon (CIFN) among HCV genotype 3 patients who
failed to respond to pegylated interferon and ribavirin.
Objectives: We aimed to assess the efficacy and safety of CIFN and ribavirin in non-responders and relapsers to pegylated interferon with
ribavirin therapy.
Patients and Methods: This open-label investigator-initiated study included 44 patients who received CIFN 15 µg /day plus ribavirin
800-1200 mg daily. In patients with an early virological response (EVR), the dose of CIFN was reduced to 15 µg thrice a week for further 36
weeks. Patients with delayed virological response continued to receive daily CIFN plus ribavirin to complete 48 weeks. The patients were
considered “non-responders” if there were less than 2 log reduction in HCV RNA at 12 weeks and detectable HCV RNA at 24 weeks.
Results: Twenty-four patients (55%) were non-responders and 20 patients were relapsers to the previous treatment with pegylated
interferon plus ribavirin (mean age 43.6 ± 9.4 years, males 25 (57%)). Nine patients were clinically cirrhotic (Child A). End of treatment
virological response was achieved in 19 (43.1%) patients and sustained virological response (SVR) occurred in 12 (27.3%). Out of these
12 patients, eight were non-responders and four were relapsers to the previous treatment. Advanced fibrosis or clinical cirrhosis was
associated with low SVR. Adverse events were fever, myalgia, anorexia, depression, and weight loss. Two patients received granulocyte
colony stimulating factor for transient neutropenia. Seven patients were given erythropoietin to improve hemoglobin, and six were
treated for mild depression. Two patients developed portosystemic encephalopathy.
Conclusions: More than one-quarter of treatment-experienced patients with HCV genotype 3 achieved SVR after re-treatment with
consensus interferon plus ribavirin.
Keywords: Hepatitis C; Genotype; Ribavirin; Treatment

1. Background
Hepatitis C virus (HCV) infection is the second most
common chronic viral infection affecting 170 million
people worldwide (1). It is responsible for 25-30% cases
of cirrhosis globally. The resultant cirrhosis is associated
with increasing risk of hepatic decompensation and hepatocellular carcinoma (HCC) (2). Sustained virological
response (SVR) after antiviral therapy may halt the progression of fibrosis with lower risk of developing HCC
and improve survival (3). However, the SVR rates depend
upon many host- and virus-related factors, including age,
gender, obesity, IL-28B genotype, stage of liver fibrosis,
HCV genotype, and baseline viral load (2, 4, 5). Treatment
with pegylated interferon (Peg-IFN) and ribavirin (RBV) is
considered as the standard treatment for hepatitis C asso-

ciated with SVR in 40-50% and up to 80% of HCV genotype
1 and 2/3 (naïve) patients, respectively (6-8). Additionally,
re-treatment with Peg-IFN and RBV can also lead to SVR in
6-15% of non-responders and 32-50% of relapsers to previous treatment with standard interferon with or without
RBV3, (3, 9, 10).
Chronic hepatitis C (CHC) patients who are non-responders or relapsers to Peg-IFN and RBV are the most
challenging population that hepatologists face with, and
the optimal approach for treatment of these patients
would be the use of direct-acting antiviral agents (DAA)
with or without Peg-IFN and RBV. Several alternative approaches were attempted in pre-DAA era such as re-treatment with alternative brand, prolonged treatment with
Peg-IFN, maintenance therapy, or use of higher doses of
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Chronic hepatitis C patients -non-responding or relapsing to Peg-IFN with RBV regimen are the most challenging population, and the optimal approach
for treatment of these patients would be the use of directly acting antiviral agents (DAA) with or without Peg-IFN and RBV. Currently, available DAA-based
regimens are approved only for genotype 1. The HCV genotype 3 is the most prevalent genotype in Pakistan. There is a need to explore alternative approaches for treatment-experienced genotype 3 patients. Data for the use of CIFN plus RBV therapy in such genotype 3 patients are scanty.
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Peg-IFN with or without RBV (10-12). However, the results
were not promising in the majority of such approaches
(2, 13). Another drug modality considered in some studies
was consensus interferon (CIFN) with or without RBV (9,
12).
CIFN is a synthetic, recombinant type-I interferon with
166 amino acids and molecular weight of 19,500 dalton
engineered by creation of a consensus sequence involving the most common amino acids found in naturally
occurring alpha interferon subtypes (14). In in-vitro cell
lines, CIFN has shown 10 fold greater antiviral efficacy
than naturally occurring by IFN alpha, and may have
finer efficacy in difficult-to-treat CHC patients (3, 15, 16).
Due to differences in dosing, heterogeneity in study
populations, and lack of comparative data with Peg-IFN
plus RBV, CIFN is not considered as the first-line agent
for treatment of HCV, although it may have a potential
role in the management of CHC patients who failed to respond to previous interferon-based therapy (15, 17). Studies evaluating the efficacy of CIFN in standard IFN therapy
failure with or without RBV have shown SVR of 5-33% and
28-58% with CIFN monotherapy among non-responders
and relapsers, respectively (18-21), while in RBV-added
regimen the SVR was further improved to 22-39% in nonresponders but remained at 26-47% in relapsers (22-26).
Most of the patients in these studies were infected with
HCV genotype 1.
In Pakistan, HCV infection has been reported to affect approximately 10 million people and is the most common
cause of cirrhosis and HCC (27). The HCV genotype type 3
is the most prevalent genotype affecting 67-87% of cases
(28). HCV genotype 3 was considered as easier to treat;
however, such data were extrapolated from subgroup
analysis in larger trials, which were mostly conducted on
a Caucasian population with genotype 1. In our clinical
practice, we often encounter the issue of treatment failure in patients with HCV genotype 3 even after treatment
with Peg-IFN and RBV. In addition, data collected from the
use of CIFN plus RBV therapy in patients with CHC due to
genotype 3, and from relapsers to Peg-IFN + RBV therapy
are scanty. Hence, there is a need to evaluate the efficacy
and tolerability of CIFN and RBV combination therapy
in CHC genotype 3 patients who relapsed or failed to respond to previous treatment with Peg-IFN and RBV.

2. Objectives

The objectives of this study were to assess the efficacy
and safety of CIFN and RBV in patients with chronic hepatitis C genotype 3 who were non-responders or relapsers
to previous therapy with Peg-IFNα 2a or 2b and RBV.

3. Patients and Methods
3.1. Study Design
This was a phase 4 open-label investigator-initiated
2

clinical trial to investigate the efficacy and safety of consensus interferon (CIFN) and ribavirin (RBV) therapy in
the treatment-experienced patients who were non-responders or relapsers to Peg-IFN and RBV. The study was
conducted at three tertiary care centers in the cities of
Karachi, Lahore, and Hyderabad, Pakistan.

3.2. Inclusion and Exclusion Criteria

The study population included consecutive patient’s ≥
18 years of age with chronic hepatitis C (CHC) infection
due to genotype 3 who were non-responders or relapsers
to previous therapy with Peg-IFNα 2a or 2b plus ribavirin.
The diagnosis of CHC was based on detectable anti-HCV
antibody (by ELISA-IV or MEIA method) and serum HCV
RNA by PCR (COBAS Amplicor, HCV qualitative assay) with
normal or elevated ALT. The patients were eligible for the
study in the absence of a prior episode of hepatic decompensation given that they had normal liver function evident by serum bilirubin < 2 mg/dL, serum albumin ≥ 3.
5 g/dL, and platelet count ≥ 75 × 103 /mcL. Patients with
upper gastrointestinal bleeding due to esophageal varices eradicated after serial esophageal variceal band ligations with or without beta-blockers, were also accepted
for the study.
Patients were excluded from the study who had associated HBV, HDV, or HIV infection, HCV related decompensated cirrhosis defined as ascites, portosystemic encephalopathy, hepatorenal syndrome, HCC, and recurrent
variceal bleeding which required premature discontinuation or dose reduction of Peg-IFN during previous treatment due to safety or tolerability issues, major psychiatric illness, hemoglobin < 10 g/dL for females and 12gr/
dL for males, WBC counts < 2.5 × 103 /mcL or neutrophil
count < 1.5 × 103 /mcL , platelets count < 75 × 103 /mcL, serum creatinine > 1.5 mg/dL, concomitant metabolic or
autoimmune liver disease, post liver transplant patients,
pregnant and lactating females, uncontrolled seizures,
severe heart disease, or other absolute contraindications
for the treatment.

3.3. Study Procedures

All consecutive patients who have visited the study centers for treatment of hepatitis C were evaluated. Those
who were found eligible and agree to participate in the
study were enrolled after informed consent. Baseline
medical history was recorded, physical examination was
done, and blood was drawn for baseline laboratory tests
including complete blood count (CBC), prothrombin
time (PT), liver function tests (LFTs), serum creatinine,
serum albumin, fasting blood sugar (FBS), and thyroid
stimulating hormone (TSH). All nucleic acid tests were
performed in the Clinical Laboratory of Karachi center
using standard techniques. HCV genotyping was done
by HCV-PCR reverse hybridization (INNOLIPA) technique,
and plasma HCV RNA levels by Real Time quantitative
assays. Liver biopsy was recommended for all patients,
Hepat Mon. 2013;13(12):e14146
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however, only 22 patients underwent for liver biopsy.
Liver biopsies were interpreted by a single experienced
histopathologist based in Karachi, using METAVIR scoring system (29). All information was collected using a
preformed data collection form.

for further 36 weeks. However, the patients were considered “non-responders” and treatment was discontinued
if there was a < 2 log10 reduction in HCV RNA from baseline at week 12. The patients with partial or delayed virological response (i.e. patients with detectable HCV RNA at
week 12 but with ≥ 2 log10 reduction in HCV RNA from
baseline) continued to receive CIFN 15 µg daily + RBV for
an additional 12 weeks (i.e. till week 24). The treatment
was discontinued when HCV RNA was detectable at week
24, and continued for responders by receiving CIFN 15 µg
daily + RBV for further 24 weeks (Figure 1). Furthermore,
end of treatment virological response (ETR) was assessed
after the completion of 48-week therapy and patients
were followed at week 72 to assess sustained virological
response (SVR).

3.4. Study Medication and Protocol

Consecutive, eligible patients who agreed to participate
in the study received CIFN 15 µg/day (INFERGEN; Three
Rivers Pharmaceuticals, LLC, USA) subcutaneously along
with RBV. RBV was given as 800 mg/day for body weight
less than 70 kg and 1200 mg/day for body weight ≥ 70
kg in 2-3 divided doses. If the patients showed undetectable plasma HCV at week 12 (early virological response or
EVR), the dose of CIFN was reduced to 15 µg thrice a week

HCV genotype 3 treatment
experienced patients (n=79)
Excluded after
evaluation = 35

CIFN µ/g’d plusRBV
800-1200 mg (n=44)
Treatment
discontinued = 3

EVR achieved
(n=37)

≥2 log reduction in
viral load at week 12
(n= 1)

CINF reduced to thrice a
week plus RBV to complete 48
weeks

HCV RNA
rechecked at
24 weeks

Treatment stopped if
breakthrough at 24
weeks (n=5)

HCV RNA riot
detected (n=0)
CIFN 15 µg/d
plus RBV for
another 24 weeks

<2 log reduction in
viral load at week 12
(n=3)
Treatment
stopped

HCV RNA detected
(n= 1)

Treatment stopped

Figure 1. The Study Algorithm

3.5. Patient’s Monitoring and Follow-Up
Patients were assessed in outpatient clinics, initially
twice weekly for one month and then every four weeks
until the end of treatment. Once the treatment ended, patients were followed at weeks 12 and 24 post-treatment.
Physical signs for hepatic decompensation, adverse effects of the antiviral therapy, complete blood count,
and ALT were recorded at each visit. To detect thyroid
dysfunction that might develop during treatment with
CIFN, TSH was rechecked at week 12. Qualitative HCV PCR
was checked at the weeks 12, 24, end of treatment, and
24 weeks afterwards. Moreover, to differentiate between
non-responders and partial responders, plasma HCV
Hepat Mon. 2013;13(12):e14146

RNA by Real Time quantitative assay was also checked at
week 12 for those who demonstrated detectable qualitative HCV PCR. Treatment was terminated in case of clinical hepatic decompensation, or hemoglobin < 7.0 g/dL,
platelets < 50 × 103 /mcL, and absolute neutrophil count
(ANC) of < 0.5 × 103 /mcL. However, erythropoietin and/or
granulocyte-colony stimulating factor (G-CSF) was given
in situations where hemoglobin was < 8 g/dL and ANC <
0.75 × 109 /mcL. Moreover, the dose of CIFN and/or RBV
were reduced in case of persistence Hb < 8 g/dL and absolute neutrophil count (ANC) < 0.75 × 103/mcL despite the
addition of erythropoietin and ribavirin. Clinical decompensation is defined as development of ascites, hepatic
hydrothorax, portosystemic encephalopathy (PSE), or
3
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variceal bleeding during treatment.

3.6. Outcome Measures

Our primary outcome was SVR. Secondary outcomes
included ETR, comparison between non-responders and
responders to therapy, drug tolerability, and safety.

3.7. Safety and Tolerability

All adverse events (AEs) and major adverse events were
recorded for patients who received at least one dose of
study medication. AEs were recorded until 30 days after
the last dose of study medication. AEs were graded from
1 to 5 (1, mild; 2, moderate; 3, severe; 4, life-threatening or
disabling; 5, death) based on the Common Terminology
Criteria for Adverse Events v4.03 (30). An AE was considered as serious if it resulted in death, could be life-threatening, required hospitalization, or resulted in persistent
or significant disability or incapacity.

3.8. Ethical Consideration

The study was conducted by maintaining compliance
with the Helsinki Declaration, and was approved by the
Ethical review committee of The Aga Khan University
Hospital and collaborating centers (1643-MED-ERC-2010).
Aims and objectives of the study, duration of treatment,
required laboratory assessment, and risks and benefits
associated with the study drugs were explained in detail. Patients were enrolled after informed consent. The
baseline laboratory tests including liver biopsy were
those tests that were routinely performed while treating
such patients; hence these baseline laboratory tests were
made at the patient’s own expense. However, the laboratory tests required during follow-ups and the study drugs
were covered by study budget. Moreover, in case of serious adverse events including hepatic decompensation,
cardiac toxicity, and bone marrow toxicity requiring hospitalization, or adjuvant treatment with erythropoietin
or G-CSF, the cost was covered by study budget. The funding agency had no access to data and was not involved in
data analysis or in writing manuscript.

3.9. Sample Size and Statistical Analysis

The sample size was calculated by assuming an overall
SVR rate of 21% (27) after treatment with CIFN and RBV,
with 95% confidence level and a bound on error of ± 8%;
an estimated sample size of 100 patients was required to
achieve a 90 % power at a 5% significance level. However,
due to funding issues, we decided to conduct a pilot study
by taking 40% of required sample size (i.e. 40 patients).
Data were entered and analyzed by using SPSS for windows version 17 (SPSS Inc., Chicago, Illinois, USA). Results
for quantitative variables were presented as mean ± standard deviation, median, or range after checking the normality and frequencies (percentages) for qualitative vari-

4

ables. Intention to treat analysis (ITT) and per-protocol
analysis (PP) was performed to estimate SVR in the study
population. Comparisons were done using Chi-square
test or Fisher exact test for categorical variables, or student t-test for continuous variables. While applying latter test, Levene’s test was used to assess equality of variances. A P value < 0.05 was taken as significant. All values
were two-tailed. To evaluate potential predicting factors
for SVR, univariate and multivariate logistic regression
analyses were performed. A P value < 0.05 was taken as
significant.

4. Results

During the recruitment phase, 79 consecutive patients
were considered for inclusion in the study; 35 patients
were excluded : 7 patients for previous episodes of decompensation, 11 for low platelets, 8 for low hemoglobin, 2 for elevated serum creatinine, 3 for being HBsAg
positive, 1 for heart disease, and 3 patients who refused
to give consent. Forty-four patients fulfilled the eligibility criteria and were enrolled, among them 24 patients
(55%) were non-responders and 20 (45%) were relapsers to
the previous treatment with Peg-IFN plus RBV. The overall
mean age was 43.7 ± 9.4 years and 25 patients (57%) were
male. The median baseline HCV viral load was 7.20x105
IU/ml (range 6.47 × 102-6.80 × 108). Seven patients suffered from diabetes, 6 from hypertension, one from
both diabetes and hypertension, and 2 from rheumatoid
arthritis. Clinically, 9 patients exhibited cirrhosis (Child
A). Twenty-two patients underwent liver biopsy of which
11 patients showed fibrosis at stage 3 or 4. Cirrhosis and
advanced fibrosis were more frequent in relapsers compared to non-responders in this cohort (12/20 vs. 4/24, P =
0.005). The baseline characteristics of study patients are
given in Table 1.
During the first 12 weeks of treatment, two patients developed hepatic encephalopathy and were taken off the
study. One patient stopped treatment due to fever and
myalgia, and three patients failed to respond. In one patient, HCV RNA was detectable but there was a 2 log reduction. So, early virological response (EVR) was achieved
in 37 (84.1%) patients: 22 non-responders and 15 relapsers
to previous treatment. At 24 weeks, five patients showed
breakthrough when they were on an alternate day regimen. Moreover, one patient with a partial response at
week-12 failed to clear the virus. So, at this point, 12 patients were off the study. The rest of 32 patients completed
the 48-week treatment (Figure 1). Two more patients were
lost to follow-up after completion of treatment leaving
behind 30 patients. However, excluding three patients
who were dropped out, 41 patients complied with the
protocol, so eligible for per-protocol evaluation for end
of treatment response (ETR). Two more patients violated
the protocol by not-returning for evaluation of SVR, leaving behind 39 patients for per-protocol analysis of SVR.

Hepat Mon. 2013;13(12):e14146

Abbas Z et al.
Table 1. Baseline Characteristics of Study Patients
Characteristics

Gender (Male/Female)
Age, y

Data
25/19

Mean ± S D

43.6 ± 9.4

Median (range)

42.5 (25-70)

Body mass index, Mean ± SD
Previous treatment, No.

26.8 ± 5.4

Non-responders

24

Relapsers

20

Mean ± SD

1.94 × 107 ± 1.08 × 108

Median (range)

7.20 × 105 (6.47 × 1026.80 × 108)

Baseline HCV RNA, IU/L

Hb%, g/dL, Mean ± SD

Total leukocyte count (× 103/mcL),
Mean ± SD
Platelets (× 103/mcL), Mean ± SD
Bilirubin, mg/dL, Mean ± SD

Alanine aminotransferase, IU/L,
Mean ± SD

Gamma glutamyltransferase, IU/L,
Mean ± SD
Alkaline phosphatase, IU/L, Mean
± SD
Albumin, g/dL, Mean ± SD

International normalization ratio
(INR), Mean ± SD
Creatinine, Mean ± SD

Fasting blood sugar, mg/dL, Mean
± SD

13.0 ± 1.8
6.4 ± 2.1
223.7 ± 92.6
0.66 ± 0.30
67 ± 58
64 ± 48
141 ± 82
4.01 ± 0.45
1.14 ± 0.16
0.7 ± 0.2
98 ± 23

Grade of inflammation (n = 22),
No.
Mild

3

Moderate

11

Severe

8

F0

1

F1

3

F2

7

F3

10

F4

1

Steatosis

5

Stage of disease (n = 22)

According to intention to treat analysis, end of treatment virological response (ETR) was achieved in 19 out of
44 patients (43.2%) which was sustained (SVR) in 12 out of
44 cases (27.3%). With per-protocol analysis, these figures
were 19 out of 41 (46.3%) and 12 out of 39 patients (30.8%),
respectively. The patients who showed SVR also exhibited
normalization of ALT. Comparing responders with nonHepat Mon. 2013;13(12):e14146

responders to CIFN plus RBV therapy, only absence of cirrhosis or advanced fibrosis was statistically significant
among other factors. (P = 0.032) (Table 2). None of diabetic patients (P = 0.084) but just one patient with hypertension (P = 0.653) achieved SVR. However, the presence of
co-morbidity was not statistically significant.
Table 2. Possible Predictors of Sustained Virological Response
(SVR)
Gender (Male/
Female)
Age, mean ±
SD, y

Previous treatment, Nonresponders/
Relapsers
Body mass
index, mean ±
SD, kg/m2
Co-morbids

Fasting blood
sugar, mean ±
SD, mg/dL)

Baseline HCV
RNA, mean ± SD,
IU/L
Hb %, mean ±
SD, g/dL

Total leukocyte
count, mean ±
SD, (× 103/mcL)

Platelets , mean
± SD, (× 103/mcL)
Bilirubin, mean
± SD, mg/dL
Alanine aminotransferase,
mean ± SD, IU/L
Gamma glutamyltransferase, mean ± SD,
IU/L
Alkaline phosphatase, mean
± SD, IU/L

Albumin, mean
± SD, g/dL

SVR, n = 12

No SVR, n = 32

P value

6/6

19/13

0.567

42.6 ± 7.9

44.0 ± 9.9

0.673

8/4

16/16

0.498

24.3 ± 2.9

27.6.0 ± 5.8

0.197

2

14

0.160

2.30 × 106 ±
3.48 × 106

2.45 × 107 ± 1.23
× 108

0.597

13.3 ± 1.5

12.9 ± 1.9

0.503

6.6 ± 2.6

6.3 ± 1.8

0.666

257 ± 117

211 ± 79

0.139

0.53 ± 0.16

0.71 ± 0.33

0.077

55± 26

71 ± 66

0.416

49 ± 19

70 ± 53

0.082

161 ± 114

133 ± 66

0.337

4.1 ± 0.29

3.9 ± 0.49

0.141

87.4 ± 7.5

104.2 ± 27.2

Advanced
fibrosis/ clinical
cirrhosis
Yes
No

Early virological response

0.086

0.032
1

15

12

25

11

17

0.163

Common side effects were fever in 40 (91%), myalgia in
5
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22 (50%), anorexia in 15 (34.1%), depression in 6 (13.6%), pallor in 5 (11.4%), and weight loss in 4 (9.1 %) patients. Most
adverse events attributed to CIFN were mild to moderate
in severity and short-lived. Two patients on daily CIFN
therapy developed neutropenia of less than 0.75 × 103/
mcL. It was dealt with through giving G-CSF and temporary dose reduction. Seven patients received erythropoietin for anemia. Six patients received selective serotonin
reuptake inhibitors (SSRIs) for mild depressive symptoms, two patients developed portosystemic encephalopathy and were dropped out of the treatment.

5. Discussion
Significant morbidity and mortality associated with
HCV and treatment failures in approximately half of all
patients with Peg-IFN plus RBV remain major concerns
for health care providers (9). SVR achievement may halt
the progression of fibrosis with lower risk of developing
HCC, and improves the survival (11). DAAs are undergoing clinical trials, and interferon-free regimens are still
not approved. Triple regimen containing boceprevir or
telaprevir, in conjunction with Peg-IFN and RBV, is approved only for genotype 1 (31). Henceforth, there is a
need to alternative antiviral therapy from the available
armamentarium for CHC genotype 3 patients who are
non-responders or relapsers to Peg-IFN and RBV therapy
to stop viral replication and ultimate hepatic decompensation, and prevent HCC. CIFN may be a treatment option
for this group of patients with CHC (3). However, generalizing results of available clinical studies evaluating
CIFN for treatment of who with previous failure in PegIFN plus RBV regimen can be challenging. This is mainly
due to wide variations in study design, dosing regimens,
duration of therapy, and heterogeneous patient populations (based on prior response to therapy) involved in
these study. Moreover, data regarding efficacy of CIFN
in relapsers were limited, and majority of the patients
(90-100%) recruited in these studies were affected by HCV
genotype 1; a genotype which responds in a different way
from genotype 3.
The preferred dose of CIFN and duration of therapy in
the setting of treatment has not been well established
(3, 15). The approved dose of CIFN varies from country to
country; for instance, in the United States, the approved
dose is 15 μg three times a week given subcutaneously,
whereas in Germany it is 9 µg three times a week (3, 17,
32). To provide more favorable kinetics and subsequent
maximal viral suppression, a daily dosing trial was attempted (17, 33, 34). However, in DIRECT trial, a daily dose
of 15 µg was found to be associated with discontinuation
of CIFN in 21% patients due to various side effects (33). On
the other hand, switching daily dosing to thrice a week
regimen for those who achieved EVR could improve the
tolerability and compliance for CIFN36. Nonetheless, the
overall frequencies of adverse effects and dose modification even with the higher doses of CIFN + RBV therapy
6

are comparable to what was reported for Peg-IFN + RBV
therapy (3).
Our patients received CIFN 15 µg/day along with RBV.
If the patients achieved EVR, CIFN dose was reduced to
15µg thrice a week for further 36 weeks. The patients with
a partial virological response continued to receive CIFN
15µg daily and RBV. The treatment was discontinued in
both groups if HCV RNA remained, or became detectable at 24 weeks. Five patients experienced breakthrough
when CIFN dose was reduced to thrice a week after initial
EVR. Probably, the trice a week dose was not sufficient
enough to keep the viral replication suppressed, and this
could have been prevented if daily dosing was continued.
Data regarding effectiveness of CIFN among patients
who failed to respond to Peg-IFN and RBV were limited
and somewhat conflicting. Overall, a SVR rate of 6% has
been reported among non-responders to Peg-IFN and
RBV in a retrospective data analysis from US Veterans Administration hospitals when treated with CIFN (35). In
another group of patients, only 10.7% of cases of non-responders to Peg-IFN plus RBV achieved SVR after 48-weeks
treatment with CIFN 15 µg/day with RBV, whereas lowering the dose of CIFN to 9 µg/day reduced SVR merely to
6.9% (33). Leevy CB retrospectively analyzed 137 patients
unable to achieve an early virological response with PegIFN + RBV, who were treated with CIFN 15 µg /day plus
RBV afterwards (36). The dose of CIFN was reduced to 15
µg thrice a week (TIW) for 36 weeks in that study if the
patient was HCV RNA negative at week 12. Overall, 37% of
patients could achieve SVR (36). In our study, all-inclusive
SVR was 27.3% and in non-responders, it was 33.3% (8/24).
Previous studies have shown that patients who relapse,
exhibit partial response, or experience breakthrough are
more likely to achieve SVR with re-treatment compared
to patients who showed null response (2, 37). A study
showed a SVR achievement of 31% in such patients retreated with CIFN and RBV (35). Our study performed on
the relapsers of genotype 3 could not clinch that much, as
SVR was achieved only in 4 out of 20 patients (20%). Our
non-responder group showed better off with one-third of
patients achieving SVR.
Due to limited funding, our study was not powered
to find out the factors predicting SVR to CIFN with RBV
therapy in genotype 3 treatment-experienced patients.
Though our patients with co-morbidity demonstrated
a low response and all patients with diabetes did not
achieve SVR, it could not achieve the significance due to
small sample size. Baseline viral load did not influence on
the outcome. Advanced fibrosis was the only parameter
of significance, which adversely affected SVR. . Just one
patient out of 16 patients with F3 or F4 fibrosis or clinical
cirrhosis could achieve SVR. It was previously shown that
genotype 3 no longer remains a privileged genotype to
respond to treatment when fibrosis advances (5, 38). The
reason why the non-responders compared to relapsers
achieved higher SVR in our study might be due to high
proportion of patients with advanced fibrosis and cirrhoHepat Mon. 2013;13(12):e14146
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sis in the latter group.
Currently, available DAA-based regimens for the treatment-experienced patients are approved only for HCV
genotype 1. The strength of this study is that we have
tried to explore an alternative approach for the retreatment of HCV patients infected with genotype 3. The data
regarding use of CIFN and RBV therapy in such patients
were scanty. The major weakness of this study appears to
be small size of the sample.
In conclusion, about a quarter of HCV genotype 3 patients previously treated with Peg-IFN and RBV benefited
from re-treatment with CIFN and RBV. However, the degree of fibrosis influenced the outcome of re-treatment.
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